FIELD: medicine, pharmaceutics.
SUBSTANCE: prodrugs are represented by formula or in which in formula (2) R1 represents an atom of hydrogen or C1-C6-alkyl group; X is C=O or C1-C3 slkylene group; R2 and R4 each independently represents a hydrogen, C1-C6-alkyl group; and R3 is C1-C6 alkyl group, and in formula (3) R1 has values specified in formula (2); n is an integer from 1 to 6; and R5 is a hydrogen atom or -COOR6 (where R6 is a hydrogen atom or C1-C6 alkyl group), where in formula (2) and (3) Y is a group, represented by formula (5), which is given in the invention formula.
EFFECT: obtaining novel water-soluble prodrugs, which cam be introduced parenterally, and which demonstrate high solubility in water are quickly turned into an active form.
12 cl, 7 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
HEXACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND THEIR USING AS ANTITUMOR AGENTS, METHOD FOR PREPARING HEXACYCLIC COMPOUNDS | 2002 |
|
RU2299212C2 |
METHOD FOR IDENTIFICATION OF ANTI-TUMOR TARGET ENZYMES | 2002 |
|
RU2319482C2 |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE | 2015 |
|
RU2683780C2 |
ANTI-HER2 ANTIBODY DRUG CONJUGATE | 2015 |
|
RU2794183C2 |
DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | 2009 |
|
RU2514937C2 |
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2664465C2 |
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2776489C2 |
HEXACYCLIC COMPOUND | 1992 |
|
RU2071476C1 |
INDOLIZINE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION OF ACTIVITY OF TESTOSTERONE-5α-REDUCTASE | 1992 |
|
RU2120942C1 |
LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, ITS PRODUCTION METHOD AND ITS USE | 2019 |
|
RU2793316C2 |
Authors
Dates
2011-03-10—Published
2005-04-08—Filed